Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of “Moderate Buy” from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $40.8182.

Several research firms have recently commented on CAPR. Cantor Fitzgerald reissued an “overweight” rating on shares of Capricor Therapeutics in a research note on Wednesday, January 14th. Oppenheimer upped their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. iA Financial set a $48.00 target price on Capricor Therapeutics in a research report on Wednesday, December 3rd. Finally, Maxim Group raised their price target on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th.

Capricor Therapeutics Stock Down 2.2%

Shares of NASDAQ CAPR opened at $27.87 on Tuesday. Capricor Therapeutics has a 12-month low of $4.30 and a 12-month high of $40.37. The firm’s 50-day simple moving average is $25.55 and its 200 day simple moving average is $14.55. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -15.48 and a beta of 0.38.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at about $28,000. Parkside Financial Bank & Trust bought a new position in Capricor Therapeutics during the 3rd quarter worth approximately $36,000. Russell Investments Group Ltd. grew its holdings in Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the period. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $43,000. Finally, GoalVest Advisory LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $59,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.